PE20211591A1 - Inhibidores de o-glicoproteina-2-acetamido-2-desoxi-3-d-glucopiranosidasa - Google Patents

Inhibidores de o-glicoproteina-2-acetamido-2-desoxi-3-d-glucopiranosidasa

Info

Publication number
PE20211591A1
PE20211591A1 PE2021000333A PE2021000333A PE20211591A1 PE 20211591 A1 PE20211591 A1 PE 20211591A1 PE 2021000333 A PE2021000333 A PE 2021000333A PE 2021000333 A PE2021000333 A PE 2021000333A PE 20211591 A1 PE20211591 A1 PE 20211591A1
Authority
PE
Peru
Prior art keywords
glucopyranosidase
acetamido
deoxy
glycoprotein
inhibitors
Prior art date
Application number
PE2021000333A
Other languages
English (en)
Spanish (es)
Inventor
Nathan Genung
Kevin M Guckian
Jeffrey Vessels
Lei Zhang
Ryan Gianatassio
Edward Yin Shiang Lin
Zhili Xin
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of PE20211591A1 publication Critical patent/PE20211591A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
PE2021000333A 2018-09-19 2019-09-18 Inhibidores de o-glicoproteina-2-acetamido-2-desoxi-3-d-glucopiranosidasa PE20211591A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862733484P 2018-09-19 2018-09-19
US201862750000P 2018-10-24 2018-10-24
PCT/US2019/051661 WO2020061150A1 (en) 2018-09-19 2019-09-18 O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors

Publications (1)

Publication Number Publication Date
PE20211591A1 true PE20211591A1 (es) 2021-08-18

Family

ID=68073263

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021000333A PE20211591A1 (es) 2018-09-19 2019-09-18 Inhibidores de o-glicoproteina-2-acetamido-2-desoxi-3-d-glucopiranosidasa

Country Status (22)

Country Link
US (2) US12180205B2 (cg-RX-API-DMAC7.html)
EP (1) EP3853226A1 (cg-RX-API-DMAC7.html)
JP (2) JP7606960B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210060513A (cg-RX-API-DMAC7.html)
CN (2) CN113166137B (cg-RX-API-DMAC7.html)
AU (1) AU2019344922B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021004739A2 (cg-RX-API-DMAC7.html)
CA (1) CA3113009A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021000646A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021004873A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210181A (cg-RX-API-DMAC7.html)
IL (2) IL315564A (cg-RX-API-DMAC7.html)
JO (1) JOP20210036A1 (cg-RX-API-DMAC7.html)
MA (1) MA53648A (cg-RX-API-DMAC7.html)
MX (1) MX2021003232A (cg-RX-API-DMAC7.html)
PE (1) PE20211591A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021550439A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202102379XA (cg-RX-API-DMAC7.html)
TW (1) TWI863926B (cg-RX-API-DMAC7.html)
UA (1) UA130690C2 (cg-RX-API-DMAC7.html)
UY (1) UY38376A (cg-RX-API-DMAC7.html)
WO (1) WO2020061150A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113166137B (zh) 2018-09-19 2024-08-16 比奥根Ma公司 O-糖蛋白-2-乙酰氨基-2-脱氧-3-d-吡喃葡萄糖苷酶抑制剂
EP3643711A1 (en) 2018-10-24 2020-04-29 Bayer Animal Health GmbH New anthelmintic compounds
AR123132A1 (es) * 2020-08-03 2022-11-02 Biogen Ma Inc Formas cristalinas de un inhibidor de la o-glucoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa
KR102533471B1 (ko) 2020-11-23 2023-05-19 (주) 메디프론디비티 O-GlcNAcase 저해 활성을 갖는 화합물 및 이의 용도
WO2025184490A1 (en) 2024-03-01 2025-09-04 Biogen Ma Inc. N-[4-fluor-5-[[(2s, 4 r)-4-[(6-methoxy-4-pyrimidinyl)oxy]- 2-methyl-1-pyrrolidinyl] methyl ]-2-thiazolyl]acetamid for use in the treatment of alzheimer disease
WO2026112144A1 (en) 2024-11-20 2026-05-28 Dewpoint Therapeutics, Inc. Modulators of beta catenin and uses thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
JP2004520347A (ja) 2001-01-15 2004-07-08 グラクソ グループ リミテッド Ldl−受容体発現のインデューサーとしてのアリールピペリジンおよびピペラジン誘導体
EP2316458A1 (en) 2004-09-20 2011-05-04 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
CN102264737A (zh) 2008-12-23 2011-11-30 雅培制药有限公司 抗病毒化合物
EP2569302A1 (en) 2010-05-13 2013-03-20 Amgen, Inc Heteroaryloxyheterocyclyl compounds as pde10 inhibitors
WO2013075084A1 (en) 2011-11-18 2013-05-23 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
US9206128B2 (en) 2011-11-18 2015-12-08 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2013078320A1 (en) 2011-11-21 2013-05-30 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
US9085583B2 (en) 2012-02-10 2015-07-21 Constellation—Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2013170072A2 (en) 2012-05-09 2013-11-14 Neurop, Inc. Compounds for the treatment of neurological disorders
EP2914604A4 (en) 2012-10-31 2016-07-20 Alectos Therapeutics Inc GLYCOSIDASE INHIBITORS AND USES THEREOF
PL2953941T3 (pl) 2013-02-11 2017-11-30 Constellation Pharmaceuticals, Inc. Modulatory enzymów modyfikujących metyl, ich kompozycje i zastosowania
WO2014159234A1 (en) * 2013-03-14 2014-10-02 Merck Patent Gmbh Glycosidase inhibitors
US9745305B2 (en) 2013-03-15 2017-08-29 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US9969716B2 (en) 2013-08-15 2018-05-15 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
KR20160100407A (ko) 2014-01-06 2016-08-23 리젠 파마슈티컬스 소시에떼 아노님 신규한 글루타미나제의 저해제
CN105753814A (zh) 2015-01-01 2016-07-13 成都贝斯凯瑞生物科技有限公司 取代氮杂环衍生物及其应用
EP3555087A1 (en) * 2016-12-16 2019-10-23 Janssen Pharmaceutica NV Monocyclic oga inhibitor compounds
EP3555094A1 (en) 2016-12-16 2019-10-23 Janssen Pharmaceutica NV Bicyclic oga inhibitor compounds
TWI654978B (zh) 2017-01-27 2019-04-01 美商美國禮來大藥廠 5-甲基-1,2,4-二唑-3-基化合物
EP3765458B1 (en) * 2018-03-14 2023-01-11 Biogen MA Inc. O-glycoprotein-2-acetamido-2-deoxy-3-d-glycopyranosidase inhibitors
US11459324B2 (en) 2018-03-14 2022-10-04 Biogen Ma Inc. O-glycoprotein-2-acetamido-2-deoxy-3-D-glycopyranosidase inhibitors
WO2019243531A1 (en) 2018-06-20 2019-12-26 Janssen Pharmaceutica Nv Oga inhibitor compounds
CN113166137B (zh) 2018-09-19 2024-08-16 比奥根Ma公司 O-糖蛋白-2-乙酰氨基-2-脱氧-3-d-吡喃葡萄糖苷酶抑制剂

Also Published As

Publication number Publication date
TW202031651A (zh) 2020-09-01
CN113166137B (zh) 2024-08-16
IL281514B2 (en) 2025-02-01
US20240308995A1 (en) 2024-09-19
CN113166137A (zh) 2021-07-23
IL281514B1 (en) 2024-10-01
KR20210060513A (ko) 2021-05-26
JP7606960B2 (ja) 2024-12-26
AU2019344922A1 (en) 2021-03-25
UY38376A (es) 2020-04-30
JP2025011144A (ja) 2025-01-23
BR112021004739A2 (pt) 2021-06-01
EP3853226A1 (en) 2021-07-28
CL2021000646A1 (es) 2021-09-03
CA3113009A1 (en) 2020-03-26
SG11202102379XA (en) 2021-04-29
US12275728B2 (en) 2025-04-15
CR20210181A (es) 2021-07-01
US12180205B2 (en) 2024-12-31
UA130690C2 (uk) 2026-04-22
JP2022500472A (ja) 2022-01-04
TWI863926B (zh) 2024-12-01
MX2021003232A (es) 2021-07-16
AU2019344922B2 (en) 2025-02-06
US20220041586A1 (en) 2022-02-10
MA53648A (fr) 2021-07-28
WO2020061150A1 (en) 2020-03-26
IL315564A (en) 2024-11-01
CN119219621A (zh) 2024-12-31
PH12021550439A1 (en) 2021-11-29
IL281514A (en) 2021-04-29
JOP20210036A1 (ar) 2021-02-25
CO2021004873A2 (es) 2021-07-30

Similar Documents

Publication Publication Date Title
PE20221628A1 (es) Compuestos inhibidores de rip1 y metodos para hacer y utilizar los mismos
PE20210128A1 (es) Inhibidores de la ectonucleotido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos
PE20171341A1 (es) Compuestos de pirazina para el tratamiento de enfermedades infecciosas
PE20151748A1 (es) Inhibidores de bace1
PE20180355A1 (es) Desacetoxitubulisina h y analogos de esta
PE20141681A1 (es) Inhibidores de btk
PE20210657A1 (es) Compuestos
PE20231746A1 (es) Compuestos de union a cereblon, composiciones de estos y metodos de tratamiento con estos
PE20161427A1 (es) Inhibidores heteroarilo de syk
PE20180160A1 (es) Sulfonilureas y compuestos relacionados y uso de estos
CL2013002299A1 (es) Compuestos derivados de heterociclos, inhibidores de la replicacion del virus de la hepatitis c; composicion farmaceutica que los comprende; util en el tratamiento de una infeccion por vhc. (divisional solicitud 689-2011).
CL2017001426A1 (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
PE20181352A1 (es) Compuestos heterociclicos que contienen bencilamina y composiciones utiles contra infeccion por micobacterias
PE20170004A1 (es) Inhibidores de biaril cinasa
PE20091972A1 (es) Compuestos heterociclicos como inhibidores del factor ixa
UA122498C2 (uk) Біциклічні похідні, спосіб їх отримання та фармацевтичні композиції, що їх містять
PE20170666A1 (es) 2-(morfolin-4-il)-1,7-naftiridinas
ECSP066375A (es) Forma cristalina gamma de clorhidrato de ivabradina, su procedimiento de preparación y composiciones farmacéuticas que la contienen
CR8249A (es) Forma cristalina gamma del clorhidrato de ivabradina, su procedimiento de preparacion y composiciones farmaceuticas que lo contienen
SV2011003855A (es) Heteroarilos sustituidos
PE20140849A1 (es) 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
CL2009000860A1 (es) Compuestos derivados de 4-fenil-4-metil-5,6-dihidro-4h-1,3-tiazina-2-amina; composiciones farmaceuticas que los contienen; y uso de los compuestos en la preparacion de medicamentos inhibidores de bace, utiles para el tratamiento de trastornos mediados por esta enzima, tal como la enfermedad de alzheimer.
PE20180024A1 (es) Triazolopirazinonas como inhibidores de pde1
PE20200342A1 (es) Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue
CL2008002268A1 (es) Compuestos derivados de amidas, moduladores del receptor taar1; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como depresion, ansiedad, estres, entre otros.